9月8日 - ** 药物开发商 Dianthus Therapeutics DNTH.O 的股价盘前上涨 17% 至 31 美元
** 在一项中期试验中，DNTH的实验性药物claseprubart改善了患有全身性肌萎缩症的成人患者的症状。
** 这项为期13周的试验共招募了65名患者，患者每两周接受一次皮下注射，剂量为300毫克、600毫克或安慰剂。
** 两种剂量的药物都能在统计学上显著改善患者的日常功能和肌肉力量，从第一周开始，一直持续到第13周
** Dianthus公司计划在第二阶段研究结束后与美国监管机构会面，并争取在2026年启动后期试验
** 截至上次收盘，DNTH 股价年累计上涨 21.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.